Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Articles
Page 3 of 42
-
Citation: Journal of Hematology & Oncology 2024 17:89
-
Targeting GPRC5D for multiple myeloma therapy
Given its nearly ubiquitous expression on plasma cells and limited expression on essential normal tissue, the G protein-coupled receptor class C group 5 member D (GPRC5D) presents a promising opportunity for u...
Citation: Journal of Hematology & Oncology 2024 17:88 -
Landscape of biallelic DNMT3A mutant myeloid neoplasms
DNA methyltransferase 3 A mutations (DNMT3AMT) are frequent in myeloid neoplasia (MN) and mostly heterozygous. However, cases with multiple DNMT3AMT can be also encountered but their clinical and genetic landscap...
Citation: Journal of Hematology & Oncology 2024 17:87 -
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promi...
Citation: Journal of Hematology & Oncology 2024 17:86 -
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia
Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the extended time for gene...
Citation: Journal of Hematology & Oncology 2024 17:85 -
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, ...
Citation: Journal of Hematology & Oncology 2024 17:84 -
c-Myc alone is enough to reprogram fibroblasts into functional macrophages
Macrophage-based cell therapy is promising in solid tumors, but the efficient acquisition of macrophages remains a challenge. Induced pluripotent stem cell (iPSC)-induced macrophages are a valuable source, but...
Citation: Journal of Hematology & Oncology 2024 17:83 -
Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia
Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pre...
Citation: Journal of Hematology & Oncology 2024 17:82 -
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Heat shock proteins are essential molecular chaperones that play crucial roles in stabilizing protein structures, facilitating the repair or degradation of damaged proteins, and maintaining proteostasis and ce...
Citation: Journal of Hematology & Oncology 2024 17:81 -
Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution
Metabolic reprogramming provides tumors with an energy source and biofuel to support their survival in the malignant microenvironment. Extensive research into the intrinsic oncogenic mechanisms of the tumor mi...
Citation: Journal of Hematology & Oncology 2024 17:80 -
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
Blinatumomab has emerged as a promising component of first-line therapy for acute B-cell precursor lymphoblastic leukemia (BCP-ALL), bolstering treatment efficacy. To mitigate CD19 selection pressure and reduc...
Citation: Journal of Hematology & Oncology 2024 17:79 -
METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma
Ferroptosis, characterized by iron-dependent lipid peroxidation, emerges as a promising avenue for hepatocellular carcinoma (HCC) intervention due to its tumor susceptibility. RNA N6-methyladenosine (m6A) modi...
Citation: Journal of Hematology & Oncology 2024 17:78 -
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Targeted protein degradation of neosubstrates plays a crucial role in hematological cancer treatment involving immunomodulatory imide drugs (IMiDs) therapy. Nevertheless, the persistence of inevitable drug res...
Citation: Journal of Hematology & Oncology 2024 17:77 -
New strategies in soft tissue sarcoma treatment
Soft tissue sarcomas (STS) have long been a formidable challenge in oncology, partly because of their rarity and diversity, which complicates large-scale studies and slows the advent of new treatments. Traditi...
Citation: Journal of Hematology & Oncology 2024 17:76 -
Correction: Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification
Citation: Journal of Hematology & Oncology 2024 17:75 -
Global burden of thyroid cancer from 1990 to 2021: a systematic analysis from the Global Burden of Disease Study 2021
Thyroid cancer (TC) is a significant global healthcare burden. However, the lack of comprehensive data has impeded our understanding of its global impact. We aimed to examine the burden of TC and its trends at...
Citation: Journal of Hematology & Oncology 2024 17:74 -
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society ...
Citation: Journal of Hematology & Oncology 2024 17:73 -
Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications
The emergence of spatial multi-omics has helped address the limitations of single-cell sequencing, which often leads to the loss of spatial context among cell populations. Integrated analysis of the genome, tr...
Citation: Journal of Hematology & Oncology 2024 17:72 -
A single-cell and spatially resolved atlas of human osteosarcomas
Osteosarcomas are intricate cellular ecosystems, where heterotypic interactions significantly influence disease progression and therapeutic outcomes. Despite their importance, a detailed understanding of their...
Citation: Journal of Hematology & Oncology 2024 17:71 -
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
Deletions and partial losses of chromosome 7 (chr7) are frequent in acute myeloid leukemia (AML) and are linked to dismal outcome. However, the genomic landscape and prognostic impact of concomitant genetic ab...
Citation: Journal of Hematology & Oncology 2024 17:70 -
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma
Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of thes...
Citation: Journal of Hematology & Oncology 2024 17:69 -
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives
Cuproptosis is a newly identified form of cell death induced by excessive copper (Cu) accumulation within cells. Mechanistically, cuproptosis results from Cu-induced aggregation of dihydrolipoamide S-acetyltra...
Citation: Journal of Hematology & Oncology 2024 17:68 -
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells
The interleukin-1 receptor accessory protein (IL1RAP) is highly expressed on acute myeloid leukemia (AML) bulk blasts and leukemic stem cells (LSCs), but not on normal hematopoietic stem cells (HSCs), providin...
Citation: Journal of Hematology & Oncology 2024 17:67 -
LncRNA-encoded peptides in cancer
Long non-coding RNAs (lncRNAs), once considered transcriptional noise, have emerged as critical regulators of gene expression and key players in cancer biology. Recent breakthroughs have revealed that certain ...
Citation: Journal of Hematology & Oncology 2024 17:66 -
Recent developments in immunotherapy for gastrointestinal tract cancers
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD lig...
Citation: Journal of Hematology & Oncology 2024 17:65 -
Correction: lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer
Citation: Journal of Hematology & Oncology 2024 17:64 -
Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study
Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal treatment, without adequate mycological evidence. ...
Citation: Journal of Hematology & Oncology 2024 17:63 -
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration
Due to the challenge for intratumoral administration, innate agonists have not made it beyond preclinical studies for efficacy testing in most tumor types. Pancreatic ductal adenocarcinoma (PDAC) has a hostile...
Citation: Journal of Hematology & Oncology 2024 17:62 -
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and ...
Citation: Journal of Hematology & Oncology 2024 17:61 -
Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)...
Citation: Journal of Hematology & Oncology 2024 17:60 -
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears
Citation: Journal of Hematology & Oncology 2024 17:59 -
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Small Cell Lung Cancer (SCLC) can be classified into transcriptional subtypes with distinct degrees of neuroendocrine (NE) differentiation. Recent evidence supports plasticity among subtypes with a bias toward...
Citation: Journal of Hematology & Oncology 2024 17:58 -
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024
Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and elimin...
Citation: Journal of Hematology & Oncology 2024 17:57 -
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC
In 2022, two new classifications of myeloid neoplasms and acute leukemias were published: the 5th edition WHO Classification (WHO-HAEM5) and the International Consensus Classification (ICC). As with prior clas...
Citation: Journal of Hematology & Oncology 2024 17:56 -
Harnessing extracellular vesicles using liquid biopsy for cancer diagnosis and monitoring: highlights from AACR Annual Meeting 2024
Liquid biopsy, an advanced technology for analyzing body fluid samples, is gaining traction in cancer diagnostics and monitoring. Blood-based liquid biopsy, particularly focusing on cell-free DNAs (cf-DNAs), c...
Citation: Journal of Hematology & Oncology 2024 17:55 -
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death recept...
Citation: Journal of Hematology & Oncology 2024 17:54 -
Lipid-based nanosystems: the next generation of cancer immune therapy
Immunotherapy has become an important part of the oncotherapy arsenal. Its applicability in various cancer types is impressive, as well as its use of endogenous mechanisms to achieve desired ends. However, off...
Citation: Journal of Hematology & Oncology 2024 17:53 -
Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting
Recent developments in menin inhibitors for relapsed or refractory acute myeloid leukemia (AML) were highlighted at the 2023 ASH Annual Meeting. Notably, revumenib showed promising efficacy, achieving a 100% O...
Citation: Journal of Hematology & Oncology 2024 17:52 -
Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification
In 2022, two updated classification systems for lymphoid neoplasms were published by the World Health Organization (WHO Classification of Haematolymphoid Tumours, 5th edition, referred to hereafter as WHO-HAEM...
Citation: Journal of Hematology & Oncology 2024 17:51 -
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial
Relapse remains a challenge after transplantation in pediatric patients with hematological malignancies. Myeloablative regimens used for disease control are associated with acute and long-term adverse effects....
Citation: Journal of Hematology & Oncology 2024 17:50 -
Advances in CAR-T-cell therapy in T-cell malignancies
Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet ach...
Citation: Journal of Hematology & Oncology 2024 17:49 -
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study
It remains a substantial challenge to balance treatment efficacy and toxicity in geriatric patients with multiple myeloma (MM), primarily due to the dynamic nature of frailty. Here, we conducted a prospective ...
Citation: Journal of Hematology & Oncology 2024 17:48 -
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study
Esophageal cancer (EC) is a highly lethal disease lacking early detection approaches. We previously identified that OTOP2 and KCNA3 were specifically hypermethylated in circulating cell-free DNA from patients ...
Citation: Journal of Hematology & Oncology 2024 17:47 -
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
The Wnt/β-catenin signaling pathway plays a crucial role in various physiological processes, encompassing development, tissue homeostasis, and cell proliferation. Under normal physiological conditions, the Wnt...
Citation: Journal of Hematology & Oncology 2024 17:46 -
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant
p53, the most frequently mutated gene in cancer, lacks effective targeted drugs.
Citation: Journal of Hematology & Oncology 2024 17:45 -
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy
Macrophages infiltrating tumour tissues or residing in the microenvironment of solid tumours are known as tumour-associated macrophages (TAMs). These specialized immune cells play crucial roles in tumour growt...
Citation: Journal of Hematology & Oncology 2024 17:44 -
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
Neutrophils play a crucial role in inflammation and in the increased thrombotic risk in myeloproliferative neoplasms (MPNs). We have investigated how neutrophil-specific expression of JAK2-V617F or CALRdel re-...
Citation: Journal of Hematology & Oncology 2024 17:43 -
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extr...
Citation: Journal of Hematology & Oncology 2024 17:42 -
Ferroptosis: principles and significance in health and disease
Ferroptosis, an iron-dependent form of cell death characterized by uncontrolled lipid peroxidation, is governed by molecular networks involving diverse molecules and organelles. Since its recognition as a non-...
Citation: Journal of Hematology & Oncology 2024 17:41 -
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type of tumor have remained grim for a long time. Currently, it is extremely challengi...
Citation: Journal of Hematology & Oncology 2024 17:40
-
Official journal of
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 29.9
5-year Journal Impact Factor: 27.1
Source Normalized Impact per Paper (SNIP): 4.489
SCImago Journal Rank (SJR): 7.522Speed 2024
Submission to first editorial decision (median days): 4
Submission to acceptance (median days): 61Usage 2024
Downloads: 3,430,659
Altmetric mentions: 1,308
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).